跳至主要内容
临床试验/NCT01615419
NCT01615419已完成不适用

A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab

Hoffmann-La Roche0 个研究点目标入组 60 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
主要终点
Proportion of patients on RoActemra/Actemra treatment at 6 months

研究概览

简要总结

This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the approved label will be followed for 6 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients, >/= 18 years of age
  • Moderate to severe rheumatoid arthritis , according to the revised ACR criteria
  • Patients initiated on RoActemra/Actemra treatment (in accordance with the local label) on their treating physicians decision

排除标准

  • RoActemra/Actemra treatment more than 8 weeks prior to enrolment visit
  • Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use
  • Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
  • History of autoimmune disease or of any joint inflammatory disease other than RA

结局指标

主要结局

Proportion of patients on RoActemra/Actemra treatment at 6 months

时间窗: approximately 2 years

次要结局

  • Efficacy: Monotherapy versus combination therapy(approximately 2 years)
  • Rates of dose modifications/interruptions(approximately 2 years)
  • Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR(approximately 2 years)
  • Use of disease-modifying anti-rheumatic drugs (DMARDs)(approximately 2 years)
  • Clinical/demographic patient characteristics at initiation of treatment(approximately 2 years)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验